Considering an early initiation of combination therapy with a low-/moderate-intensity statin and ezetimibe, novel parenteral PCSK9 modulators and BA can provide safe and efficient lipid management, translating into a decrease in the rate of CV events, allograft rejection and vasculopathy. Here, PCSK9 is linked to vascular disorder.